# Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors

> **NCT01285453** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Advanced or Recurrent Solid Tumors

## Interventions

- **DRUG:** vadimezan

## Key facts

- **NCT ID:** NCT01285453
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01285453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01285453, "Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01285453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*